Will This Spinoff's Drug Save Shareholders?
Abbott Laboratories (NYS: ABT) is in the midst of some dramatic new plans. The company will soon spin off its branded pharmaceuticals business into a new entity called AbbVie. The original Abbott Laboratories will still maintain a solid mix of health care businesses. But the new spinoff has many more dynamic questions around it, since it will be heavily reliant on Abbott's powerhouse autoimmune drug, Humira, which is quickly becoming the world's best seller. In this video, Motley Fool health care analyst Brenton Flynn outlines AbbVie's situation in more detail and points out one area that could hold the key to AbbVie's future after Humira loses patent protection.
The impending spinoff of Abbott's branded-drug business is a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.
The article Will This Spinoff's Drug Save Shareholders? originally appeared on Fool.com.Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.